Long-term medical utilization following ventilator-associated pneumonia in acute stroke and traumatic brain injury patients: a case-control study by Yang, Chih-Chieh et al.
RESEARCH ARTICLE Open Access
Long-term medical utilization following ventilator-
associated pneumonia in acute stroke and
traumatic brain injury patients: a case-control study
Chih-Chieh Yang
1, Nai-Ching Shih
1, Wen-Chiung Chang
2, San-Kuei Huang
3 and Ching-Wen Chien
4*
Abstract
Background: The economic burden of ventilator-associated pneumonia (VAP) during the index hospitalization has
been confirmed in previous studies. However, the long-term economic impact is still unclear. The aim of this study
is to examine the effect of VAP on medical utilization in the long term.
Methods: This is a retrospective case-control study. Study subjects were patients experiencing their first traumatic
brain injury, acute hemorrhagic stroke, or acute ischemic stroke during 2004. All subjects underwent endotracheal
intubation in the emergency room (ER) on the day of admission or the day before admission, were transferred to
the intensive care unit (ICU) and were mechanically ventilated for 48 hours or more. A total of 943 patients who
developed VAP were included as the case group, and each was matched with two control patients without VAP
by age ( ± 2 years), gender, diagnosis, date of admission ( ± 1 month) and hospital size, resulting in a total of
2,802 patients in the study. Using robust regression and Poisson regression models we examined the effect of VAP
on medical utilization including hospitalization expenses, outpatient expenses, total medical expenses, number of
ER visits, number of readmissions, number of hospitalization days and number of ICU days, during the index
hospitalization and during the following 2-year period.
Results: Patients in the VAP group had higher hospitalization expenses, longer length of stay in hospital and in
ICU, and a greater number of readmissions than the control group patients.
Conclusions: VAP has a significant impact on medical expenses and utilization, both during the index
hospitalization during which VAP developed and in the longer term.
Keywords: ventilator-associated pneumonia, medical utilization, longitudinal study, ICU, traumatic brain injury,
acute hemorrhagic stroke, acute ischemic stroke
Background
Nosocomial infections have a great impact on morbidity
and mortality among hospitalized patients, and can sig-
nificantly prolong hospital stay and increase medical
expenses [1,2]. Among all nosocomial infections, hospi-
tal-acquired pneumonia is the second most frequent,
being only marginally less common than urinary tract
infection (UTI). Hospital-acquired pneumonia has the
highest mortality rate and accounts for 60% of deaths
associated with nosocomial infections [3]. Patients who
are admitted to the intensive care unit (ICU) and receive
invasive mechanical ventilation have the highest risk of
nosocomial pneumonia, or ventilator-associated pneumo-
nia (VAP). It has previously been reported that 10% to
24% of hospitalized patients who received mechanical
ventilation for more than 48 hours will develop VAP
[4,5]. In some developed countries the incidence of VAP
has been reported to range from 6 to 37 per 1,000 venti-
lator-days [3,5-8], with a lower rate of 1.7 per 1,000 venti-
lator-days in long-term acute care hospitals [9]. The rates
are higher in developing countries, ranging from 10 to
41.7 per 1,000 ventilator-days [10].
Many previous studies have found that VAP results in
huge clinical and economic losses. The mortality rate of
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than the mortality rate without VAP [1,4,8,11-16].
Numerous studies have provided evidence that VAP can
lead to significant increases in several important medical
utilization items. When compared to patients without
VAP, those who developed VAP spent an extra 6 to 22
days in ICU [3-5,8,12,15-19], were hospitalized for an
extra 10 to 25 days [5,12,17], underwent an extra 5 to 12
days of ventilation [5,18,19], and cost an extra
USD10,019 to USD41,000 in hospitalization expenses
[4,5,12,17]. One Canadian study showed that an extra
17,000 ICU days per year could be attributed to VAP,
which accounted for 2% of total ICU days and USD39.3
million in increased medical expenditure [3].
The incidence of VAP among hospitalized patients,
especially critically ill patients, is substantial and causes
significant negative outcomes. Previous studies on medi-
cal utilization in VAP have been limited to assessing
medical expenses and the length of stay during the index
hospitalization. The impact of VAP on long-term medical
utilization is, however, still unclear. The main purpose of
this study is to estimate the effects of VAP on medical
expenses and utilization in the long term, after discharge
from the index hospitalization. Previous studies did not
focus specifically on patients who had the least possibility
of being admitted with community-acquired pneumonia
[8,12,15,16]. To avoid the confounding effects of commu-
nity-acquired pneumonia or other hospital-acquired
pneumonia, we selected only patients who were admitted
to hospital with traumatic brain injury, acute hemorrha-
gic stroke, or acute ischemic stroke. A previous study
indicated that trauma was a risk factor for the develop-
ment of VAP[17], and that trauma patients are usually
intubated emergently and then transferred to the ICU for
further observation. This study therefore selected only
acute stroke and traumatic brain injury patients who
were transferred directly from the emergency room (ER)
to the ICU, without admission to a ward. This should
avoid the inclusion of cases of HAP which were acquired
on the ward, and should reduce the possibility of over-
estimation or under-estimation of medical utilization
resulting from VAP.
Methods
Data source
This study analyzed data from the 2003-2006 National
Health Insurance Research Database (NHIRD) of Taiwan,
released by the National Health Research Institutes
(NHRI) of Taiwan for public research purposes. The
NHIRD is a database of all medical care claims data,
including outpatient, ER and inpatient care, of more than
98% of the 23 million people of Taiwan. It is therefore
one of the largest and most complete nationwide popula-
tion-based datasets in the world. Information in this
database includes diagnoses according to the Interna-
tional Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes, age, gender, detailed
medical expenditures, treatments, prescriptions from
each medical care interaction and hospital size. Data in
t h eN H I R Dt h a tc o u l db eu s e dt oi d e n t i f yp a t i e n t so r
care providers, including healthcare institutions and phy-
sicians, is encrypted before being sent to the NHRI for
database construction and is encrypted again before
being released to each researcher. Theoretically, it is
impossible to query the data in a way that would identify
individuals. All researchers who wish to use the NHIRD
and its data subsets are required to sign a written agree-
ment declaring that they do not intend to attempt to
obtain information that could potentially violate the priv-
acy of patients or care providers. This study was evalu-
ated and approved by the NHRI for analysis (Application
and Agreement Number: 99066 and 99167). The NHRI
guidance committee granted ethical approval.
Study subjects
The subjects included in the VAP (case) group were
selected using the following steps. First we selected
patients presenting with their first traumatic brain injury
(ICD-9-CM codes 852, 853), acute hemorrhagic stroke
(ICD-9-CM codes 430-432), or acute ischemic stroke
(ICD-9-CM codes 433-436) who also had ICD-9-CM
codes 481, 482, 483 and 486 (to identify those with pneu-
monia) during their index hospitalization. From this
group, we selected those who were transferred directly
from the ER to the ICU and received mechanical ventila-
tion for 48 hours or more. Of these, we selected those
who underwent endotracheal intubation in the ER on the
day of admission or the day before admission. We used
the definition of hospital-acquired pneumonia in the
“Clinical Practice Guidelines for Pneumonia” published
by NHRI, Taiwan [20]. This definition requires newly-
developed infiltration on chest X-ray within 48 hours
after admission, plus at least two of the following three
conditions: 1) temperature increase of ≥1°C, or tempera-
ture ≥38.3°C or <35°C; 2) white blood cell count increase
of >25%, or count of >10,000/μL or <3000/μL; or 3) >25
neutrophils per low-power field (×100) on Gram stain of
sputum. The control group was selected from subjects
without VAP. Each VAP case was matched with two con-
trol patients for age ( ± 2 years), gender, diagnosis at
admission, date of admission ( ± 1 month) and hospital
size. Both case and control groups excluded patients who
died during the index hospitalization and who had a
record of pneumonia during the year before admission,
to facilitate the evaluation of medical utilization after dis-
charge and to ensure that the pneumonia had developed
after admission. A total of 1,367 patients met inclusion
criteria for the case group and 4,241 met inclusion
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943 eligible patients in the case group and 1,868 patients
in the control group. These patients were followed up for
2 years after the index hospitalization. All of the 2,802
study subjects received positive pressure ventilation.
Variables
The dependent variables of this study were medical
expenses and utilization during the index hospitalization
and during the 2-year period after discharge. These
included hospitalization expenses, outpatient expenses,
total medical expenses (sum of the expenses in outpatient
departments, inpatient departments and ER), number of
ER visits, number of readmissions, number of hospitaliza-
tion days and number of ICU days. Medical expenses are
presented in USD (average 2006 exchange rate 1.00 USD
= 32.71 NTD). Among these dependent variables, outpa-
tient expenses, total medical expenses, number of ER vis-
its, and number of readmissions were only measured for
the 2-year follow-up period. The main independent vari-
able was whether or not a patient acquired VAP during
the index hospitalization. Control variables were age,
gender, diagnosis at admission, number of ventilation
days during index hospitalization, basic health status of
the patient, and hospital size of the index hospitalization.
The basic health status was evaluated by the number of
Elixhauser comorbidities [21] and whether or not there
was a history of chronic respiratory disease. The hospital
size was categorized as medical center (≥ 500 acute
beds), regional hospital (500-250 acute beds) or district
hospital (≤ 250 acute beds).
Statistical analysis
SAS 9.1 software (SAS Institute Inc., Cary, NC) was used
for all data processing and statistical analyses. Descriptive
statistics including frequency, percentage, mean and stan-
dard deviation of the independent and dependent vari-
ables were calculated. Chi-square tests and t-tests were
used to examine the differences between the two groups
for the control and dependent variables. The impact of
VAP on medical expenses and utilization was analyzed
by regression models after adjusting for age, gender, diag-
nosis, ventilation days, hospital size, number of Elixhau-
ser comorbidities and history of chronic respiratory
disease. Since the medical expenses in our study violated
the assumption of a normal distribution, we used robust
regression to diminish the impact of outliers during the
modeling of the effect of VAP on medical expenses, and
also undertook logarithmic transformation. As the medi-
cal utilization measures were discrete and countable vari-
ables, Poisson regression models were applied to examine
the effects of VAP on these variables. We described the
results of Poisson regressions by exp (b). A p-value of
less than or equal to 0.05 was considered to be statisti-
cally significant.
Results
Table 1 shows patient characteristics and medical
expenses and utilization data for all 2,802 study subjects.
The diagnosis at admission was traumatic brain injury in
22.4%, acute hemorrhagic stroke in 43.4% and acute
ischemic stroke in 34.2%. Among all study subjects, 67.5%
were male, with a mean ( ± standard deviation, SD) age of
65.8 ± 15.1 years and 1.8 ± 1.7 Elixhauser comorbidities.
The case group had a significantly longer duration of ven-
tilation than the control group (16.1 vs. 12.7 days, p <
0.001). There was no significant difference in the preva-
lence of history of chronic respiratory disease between the
two groups.
With regard to medical expenses and utilization, the
patients with VAP had higher hospitalization expenses
during both the index hospitalization (USD14,063 vs.
USD12,294, p < 0.001) and the follow-up period
(USD17,840 vs. USD15,156, p < 0.01), higher total medi-
cal expenses (USD20,960 vs. USD18,507, p <0 . 0 1 )a n da
greater number of readmissions (4.6 vs. 4.0, p < 0.01)
during the follow-up period, more hospitalization days
during both the index hospitalization (45.6 vs. 40.8, p <
0.001) and the follow-up period (123.6 vs. 104.8, p <
0.01), and more ICU days during both the index hospita-
lization (20.8 vs. 16.2, p < 0.001) and the follow-up period
(4.7 vs. 3.6, p < 0.01).
The results of the regression models estimating the
impact of VAP on medical utilization during the index
hospitalization with adjustment for demographic vari-
ables, basic health status, and characteristics of the
index hospitalization are shown in Table 2. Hospitaliza-
tion expenses were 5.9% higher in the VAP group than
in the control group. Hospitalization days were
increased by 0.3% and ICU days were increased by
13.2% in the VAP group. Diagnosis, hospital size, history
of chronic respiratory disease, ventilation days and num-
ber of Elixhauser comorbidities were also significantly
associated with medical utilization during the index
hospitalization.
Table 3 shows that number of readmissions was 5.7%
higher in the VAP group than in the control group.
Hospitalization days were increased by 5.4% and ICU
days were increased by 26.5% in the VAP group. How-
ever, no significant differences were observed in hospita-
lization expenses, outpatient expenses, total medical
expenses or the number of ER visits. Patients who were
older, male, had a diagnosis of stroke, had a greater
number of ventilation days, and had more Elixhauser
comorbidities were found to have a higher rate of medi-
cal utilization.
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This study expands on the existing evidence that VAP
increases medical expenses and utilization during the
index hospitalization by exploring the impact of VAP for
a 2-year period following discharge. Analysis of longitudi-
nal data shows that VAP results in substantially increased
medical expenses and utilization in the longer term. The
use of a nation-wide database, namely the NHIRD, which
includes information regarding diseases, medical expen-
ditures and utilization for more than 98% of the popula-
tion of Taiwan, enabled us to include cross-hospital
analysis.
Even though the differences between the VAP and con-
trol groups were not large enough to be clinically signifi-
cant in some of the dependent variables with statistical
significance, such as the number of readmissions, we still
believe that the impact of VAP is considerable from a
population perspective. We found that outpatient
expenses were not higher in the VAP group than in the
control group. To further explore this paradoxical phe-
nomenon, we further evaluated the data and found that
some VAP patients had been discharged to nursing
homes of the same hospital since the hospitalization.
These VAP patients therefore did not utilize outpatient
services, resulting in lower outpatient expenses in this
group.
In both the case and control groups, medical expenses
were lower than figures given by prior studies undertaken
in other countries. This is expected because the cost of
medical care is lower in Taiwan than in most Western
countries [17]. For example, the average cost per ICU day
in Canada was estimated at USD1,978 (NTD 64,692) [3],
while the highest cost per ICU day in Taiwan in our
study was USD196 (NTD6,400).
Table 1 Characteristics and medical utilization in the case and control groups
Total
(n = 2,802)
Case group (n = 943) Control group (n = 1,868) p-value
Basic characteristics
Age
a, mean ± SD 65.8 ± 15.1 65.8 ± 15.1 65.8 ± 15.04 N.A.
Gender
b, n (%) N.A.
Female 912(32.5) 304(32.5) 608(32.5)
Male 1,890(67.5) 630(67. 5) 1,260(67. 5)
Diagnosis at hospitalization
b, n (%) N.A.
Traumatic brain injury 627(22.4) 209(22.4) 418(22.4)
Acute hemorrhagic stroke 1,215(43.4) 405(43.4) 810(43.4)
Acute ischemic stroke 960(34.2) 320(34.2) 640(34.2)
Hospital size
b, n (%) N.A.
Medical center 1,284(45.8) 428(45.8) 856(45.8)
Regional hospital 1,302(46.5) 434(46.5) 868(46.5)
District hospital 216(7.7) 72(7.7) 144(7.7)
Chronic respiratory disease history
b, n (%) 0.751
No 2,159(77.1) 723(77.4) 1,436(76.9)
Yes 643(22.9) 211(22.6) 432(23.1)
Ventilation days
a, mean ± SD 13.8 ± 10.2 16.1 ± 10.5 12.7 ± 9.9 <0.001
Number of Elixhauser comorbidities
a, mean ± SD 1.8 ± 1.7 1.8 ± 1.7 1.8 ± 1.7 0.841
Utilizations during the index hospitalization
Hospitalization expenses
a, mean ± SD 12,883 ± 9,016 14,063 ± 8,999 12,294 ± 8,969 <0.001
Hospitalization days
a, mean ± SD 42.4 ± 32.7 45.6 ± 33.2 40.8 ± 32.34 <0.001
ICU days
a, mean ± SD 17.7 ± 12.3 20.8 ± 12.9 16.2 ± 11.6 <0.001
Utilizations during the follow-up period
Hospitalization expenses
a, mean ± SD 16,050 ± 23,000 17,840 ± 23,354 15,156 ± 22,774 0.004
Outpatient expenses
a, mean ± SD 3,274 ± 4,663 3,120 ± 4,863 3,350 ± 4,559 0.218
Total medical expenses
a, mean ± SD 19,324 ± 22,694 20,960 ± 23,114 18,507 ± 22,442 0.007
Number of ER visits
a, mean ± SD 1.7 ± 2.6 1.7 ± 2.6 1.7 ± 2.6 0.509
Number of readmissions
a, mean ± SD 4.2 ± 4.5 4.6 ± 4.6 4.0 ± 4.5 0.003
Hospitalization days
a, mean ± SD 111.1 ± 170.7 123.6 ± 174.3 104.8 ± 168.6 0.006
ICU days
a, mean ± SD 3.9 ± 11.0 4.7 ± 11.9 3.6 ± 10.5 0.007
a t-test;
b chi-square test
N.A. Not applicable
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is not limited to the duration of hospitalization, but will
affect many aspects of patients’ lives after discharge as well
as society as a whole. Areas affected include increased
antibiotic costs, increased microbial resistance, the devel-
opment of secondary infections, and the development of
various other complications [3]. In addition to a longer
length of stay and higher medical expenditure, patients
who develop a nosocomial infection have been found to
have a higher risk of complications including shock, renal
failure, respiratory failure, irreversible ventilator support,
heart failure, neurological failure, liver failure and death
[1]. Our results are consistent with these previous findings,
showing that VAP has a long term impact on medical
expenses and utilization, which may be a consequence of
these complications. Further studies are needed to investi-
gate the long-term pathophysiological effects of VAP.
There is ongoing discussion exploring whether increased
medical utilization is a consequence of VAP, or simply a
feature of the frailer patients who have a higher risk of
acquiring VAP. This can be evaluated using well-matched
VAP and control groups. We designed a case-control
study with strict matching of variables including age, gen-
der, diagnosis, date of admission and hospital size, and
were therefore able to eliminate the confounding effects of
these characteristics on medical expenses and utilization,
and enhance comparability between the case and control
groups. We found no significant differences in the preva-
lence of history of chronic respiratory disease or in the
number of Elixhauser comorbidities between the case and
control groups, confirming that the groups were well
matched.
Some limitations of this study should be noted. First,
the accuracy of the VAP diagnosis could not be verified
by directly examining medical records or laboratory
reports, due to the limitation of the NHIRD being an
administrative database. We were not able to obtain spe-
cific VAP information from the ICD-9-CM codes of the
NHIRD. However, the definition of VAP in this study
was very strict; subjects in the case group all underwent
endotracheal intubation in the ER on the day of admis-
sion or the day before admission, were admitted directly
from the ER to the ICU, received mechanical ventilations
for 48 hours or longer, and developed pneumonia. As the
patients were admitted directly from the ER to the ICU
without admission to a ward, we were able to exclude
other causes of hospital-acquired pneumonia. We have
confidence in the diagnoses because the Bureau of
National Health Insurance (BNHI) has established strict
review procedures to avoid miscoding and inappropriate
claims. Second, we lack information on disease severity
and other basic physical characteristics, such as Glasgow
Table 2 Regression models of medical utilization during the index hospitalization
Hospitalization expenses
b Hospitalization days
c ICU days
c
bb b
VAP
No (control group)
a
Yes (case group) 1.059** 0.003*** 0.132***
Age 0.999 -0.001*** 0.001*
Gender
Female
a
Male 1.010 0.018** -0.005
Diagnosis at hospitalization
Traumatic brain injury
a
Acute hemorrhagic stroke 1.087*** 0.056*** 0.075***
Acute ischemic stroke 0.970 0.117*** 0.046**
Hospital size
Medical center
a
Regional hospital 0.746*** -0.157*** -0.036***
District hospital 0.476*** -0.387*** -0.228***
Chronic respiratory disease history
No
a
Yes 0.922** -0.045*** -0.027*
Ventilation days 1.036*** 0.023*** 0.032***
Number of Elixhauser comorbidities 1.022*** 0.028*** 0.010**
R-Square 0.353
a Reference group;
b robust regression;
c Poisson regression
*p < 0.05; **p < 0.01; ***p < 0.001
Yang et al. BMC Health Services Research 2011, 11:289
http://www.biomedcentral.com/1472-6963/11/289
Page 5 of 7Coma Score, stroke scale, swallowing function and ade-
quacy of cough, which may have an impact on the level
of medical utilization. To correct this potential bias, we
included three variables in the regression models as
proxies for underlying health condition: ventilation days,
the number of Elixhauser comorbidities, and a history of
chronic respiratory disease. In the multivariable analysis
models, we adjusted these confounders to investigate the
individual effect of VAP on medical expenses and utiliza-
tion. This is an advantage of the present study since most
previous studies evaluated the economic outcomes of
VAP using case-control studies with no adjustment for
potential confounders [1,5,18,19].
The impact of VAP on medical expenses not only causes
considerable economic burdens on health insurers, but
also results in substantial losses for hospitals. Even though
the Unites States and Germany have different healthcare
systems, studies in both countries have demonstrated that
the medical expenses reimbursed by health insurers for
nosocomial infections were far less than the total cost to
the hospitals [19,22]. The importance of VAP prevention
is therefore not limited to improving the health outcomes
of patients and their quality of care. For hospitals, the pre-
vention of VAP has great significance in terms of cost con-
tainment and efficient medical care delivery. According to
one study in Canada, a 50% reduction in the incidence of
VAP could reduce medical expenditure by about USD21.4
million per year [3]. As the data analyzed in the present
study were National Health Insurance claims data, we
were only able to calculate the expenses reimbursed by the
BNHI of Taiwan, and other expenditures covered by hos-
pitals and patients were not included. The total impact of
VAP on medical expenses is therefore likely to be even
higher than the estimation presented in this study.
Conclusions
In conclusion, VAP has a significant impact on medical
expenses and utilization, during both the index hospitali-
zation and in the longer term. As in other developed
countries, Taiwan is confronted with the pressures of an
Table 3 Regression models of medical utilization during the 2-year follow-up period
Hospitalization
expenses
b
Outpatient
expenses
b
Total medical
expenses
b
Number of ER
visits
c
Number of
readmissions
c
Hospitalization
days
c
ICU
days
c
bb b b bb b
VAP
No (control group)
a
Yes (case group) 1.103 0.934 1.064 -0.013 0.057** 0.054*** 0.265***
Age 1.006** 0.995*** 1.011*** 0.005*** 0.008*** 0.008*** 0.020***
Gender
Female
a
Male 1.229** 0.978 1.257*** 0.256*** 0.178*** 0.134*** 0.420***
Diagnosis at
hospitalization
Traumatic brain
injury
a
Acute hemorrhagic
stroke
1.264** 1.543*** 1.465*** 0.124** 0.217*** 0.333*** 0.462***
Acute ischemic
stroke
1.411*** 1.088 1.438*** 0.083 0.203*** 0.373*** 0.622***
Hospital size
Medical center
a
Regional hospital 0.915 0.885 0.946 -0.034 -0.032 -0.124*** 0.211***
District hospital 0.924 0.615*** 0.792* -0.298*** -0.056 -0.131*** 0.296***
Chronic respiratory
disease history
No
a
Yes 0.951 0.810** 0.856* -0.068 -0.040 -0.022*** -0.030
Ventilation days 1.034*** 0.990*** 1.031*** -0.009*** 0.019*** 0.030*** 0.007***
Number of Elixhauser
comorbidities
1.072*** 1.040* 1.086*** 0.066*** 0.031*** 0.005*** 0.105***
R-Square 0.091 0.028 0.087
aReference group;
b robust regression;
c Poisson regression
*p < 0.05; **p < 0.01; ***p < 0.001
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the treatment of critically ill patients. In this context, the
use of mechanical ventilation is likely to increase in the
future, which further increases the importance of VAP
prevention. Hospital administrators and health policy
makers have a responsibility to enhance their efforts to
prevent VAP, both to improve quality and outcomes of
medical care and to contain costs.
The major finding of this study is that the significant
impact of VAP on medical expenses and utilization con-
tinues beyond the index hospitalization to the longer term.
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